SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle
cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]). Part 1
of the study will determine the activity of SCH 727965 treatment in participants with MCL and
participants with B-CLL. Part 2 of the study will determine the activity of SCH 727965
treatment in participants who experienced disease progression after standard treatment with
the comparator drug during Part 1.